Modality
Vaccine
MOA
AHRant
Target
SOS1
Pathway
Complement
Angelman
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
Nov 2021
→ Aug 2025
Phase 1Current
NCT03562532
1,501 pts·Angelman
2021-11→2025-08·Completed
1,501 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-138mo agoInterim· Angelman
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1
Complet…
Catalysts
Interim
2025-08-13 · 8mo ago
Angelman
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03562532 | Phase 1 | Angelman | Completed | 1501 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |